Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8553112 | 0.84 | PLAAT3 (0.55) | TRPV1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8443451 | 0.84 | TRPV1 (0.73) | TRPV1KMT2AHPGDHDAC3HDAC4 | |
| SCHEMBL23148266 | 0.81 | TRPV1 (0.53) | TRPV1KMT2AHPGDHDAC3HDAC4 | |
| SCHEMBL7011664 | 0.79 | HPGD (0.64) | HPGDNPC1RAB9ALMNA | |
| SCHEMBL1041910 | 0.77 | L3MBTL1 (0.74) | TRPV1KMT2AHPGDNPC1RAB9A | |
| SCHEMBL20740269 | 0.76 | LMNA (0.68) | KMT2AHPGDRAB9ALMNA | |
| SCHEMBL4406319 | 0.76 | LMNA (0.68) | KMT2AHPGDRAB9ALMNA | |
| SCHEMBL16853230 | 0.75 | ALDH1A1 (0.59) | KMT2AHPGDHDAC3HDAC4HDAC1 | |
| SCHEMBL23475919 | 0.75 | ALDH1A1 (0.59) | KMT2AHPGDHDAC3HDAC4HDAC1 | |
| SCHEMBL16853225 | 0.75 | ALDH1A1 (0.59) | KMT2AHPGDHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028955-B1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 2003-07-16 | — | — | EP | disclosed |
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | HICKEY DEIRDRE MARY BERNADETTE (GB) | 2002-08-29 | — | — | US | disclosed |
| US-6417192-B1 | DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-09 | — | — | US | disclosed |
| EP-1028955-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SmithKline Beecham p.l.c. (GB) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024420-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 1999-05-20 | — | — | WO | disclosed |
| EP-0840725-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1998-05-13 | — | — | EP | disclosed |
| EP-0799200-A1 | SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-10-08 | — | — | EP | disclosed |
| EP-0788478-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-13 | — | — | EP | disclosed |
| WO-1997002242-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | PLA2G7, PLA2G1B, PLA2G4C | TRPV1 3263/4885KMT2A 3285/4885HPGD 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.